Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 31 4. Terreni, M.; Taccani, M.; Pregnolato, M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Per- spectives. Molecules 2021, 26, 2671, doi:10.3390/ molecules26092671. 5. Jin, Y.; Li, W.; Zhang, H.; et al. e Post-Antibiotic Era: A New Dawn for Bacteriophages. Biology (Basel) 2023, 12, 681, doi:10.3390/biology12050681. 6. Yang, Q.; Le, S.; Zhu, T.; et al. Regulations of Phage erapy Across the World. Frontiers in Microbiology 2023, 14, doi:10.3389/fmicb.2023.1250848. 7. He, S.; Gui, J.; Xiong, K.; et al. A Roadmap to Pul- monary Delivery Strategies for the Treatment of Infec- tious Lung Diseases. Journal of Nanobiotechnology 2022, 20, 101, doi:10.1186/s12951-022-01307-x. 8. Flint, R.; Laucirica, D.R.; Chan, H.-K.; Stability Considerations for Bacteriophages in Liquid Formu- lations Designed for Nebulization. Cells 2023, 12, 2057, doi:10.3390/cells12162057. 9. Malik, D.J. Approaches for Manufacture, For- mulation, Targeted Delivery and Controlled Release of Phage-Based erapeutics. Current Opinion in Biotechnology 2021, 68, 262-271, doi:10.1016/j. copbio.2021.02.009. 10. Strathdee, S.A.; Hatfull, G.F.; Mutalik, V.K.; et al. Phage erapy: From Biological Mecha- nisms to Future Directions. Cell 2023, 186, 17-31, doi:10.1016/j.cell.2022.11.017. 11. Venturini, C.; Petrovic Fabijan, A.; Fajardo Lubian, A.; et al. Biological Foundations of Suc- cessful Bacteriophage erapy. EMBO Molecu- lar Medicine 2022, 14, e12435, doi:10.15252/ emmm.202012435. 12. Chang, R.Y.K.; Wallin, M.; Lin, Y.; et al. Phage erapy for Respiratory Infections. Advanced Drug Delivery Reviews 2018, 133, 76-86, doi:10.1016/j. addr.2018.08.001. 13. de Freitas Almeida, G.M.; Hoikkala, V.; Ravantti, J.; et al. Mucin Induces CRISPR-Cas Defense in an Opportunistic Pathogen. Nature Communications 2022, 13, 3653, doi:10.1038/s41467-022-31330-3. 14. Kim, M.K.; Suh, G.A.; Cullen, G.D.; et al. Bacteriophage erapy for Multidrug-Resistant Infections: Current Technologies and erapeutic Approaches. Journal of Clinical Investigation 2025, 135, e187996, doi:10.1172/JCI187996. 15. Zalewska-Piątek, B. Phage erapy—Chal- lenges, Opportunities and Future Prospects. Pharma- ceuticals 2023, 16, 1638, doi:10.3390/ph16121638. 16. Hoe, S.; Semler, D.D.; Goudie, A.D.; et al. Respirable Bacteriophages for the Treatment of Bac- terial Lung Infections. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2013, 26, 317-335, doi:10.1089/jamp.2012.1001. recent studies, the Osmohaler™ (Syntara Ltd., Frenchs Forest, New South Wales, Australia) is the most- used DPI for phage dry powders. Phage recovery ranges from 20-80% for phage powder formulations, depending on drying method and formulation. e FPF achieved using the Osmohaler ranged between 50-80%, with lung dose spanning 10 4 -10 8 PFU [54- 57]. Aerosolization losses and phage dose delivered are strongly dependent on formulation composition and powder properties. Limited studies have evalu- ated the effect of DPI type on aerosolization. Further investigation of formulation-device compatibility is therefore required to improve phage aerosolization from dry powders. Development of a stable phage- based DPI is a complex interplay of the process, excipients, overall composition, device compatibility and storage conditions. Conclusion Phages represent a promising alternative to conven- tional antibiotics and several studies have demon- strated their potential for treatment of respiratory infections. Phage viability loss during manufac- turing, storage and delivery is a major hurdle in development of phage-based products. Phage stabi- lization for inhaled delivery might be managed using formulation strategies such as excipients, encapsula- tion and the production of dry powders. Phage via- bility loss during these processes may be unavoidable but could be reduced with process optimization and use of gentler processes. Phage viability challenges might be addressed by identifying a compatible device combination for a given phage. Also, interac- tion of phages with the lung's physiological barriers is needed to ensure optimal phages reach the infec- tion site and exhibit favorable antibacterial activity. Overall, phage loss mitigation strategies, careful for- mulation design and better understanding of phage pharmacokinetics could help make inhaled phages a viable therapy. Further research and investigation into formulation strategies, device compatibility and improvements in phage stability during aerosoliza- tion and storage may also help advance the success of inhaled phage therapy. References 1. Murray, C.J.L.; Ikuta, K.S.; Sharara, F.; et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. e Lancet 2022, 399, 629-655, doi:10.1016/S0140-6736(21)02724-0. 2. O'Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Gov- ernment of the United Kingdom; 2016. 2022, 10. 3. Catalano, A.; Iacopetta, D.; Ceramella, J.; et al. Antibiotic-Resistant ESKAPE Pathogens and COVID-19: e Pandemic Beyond the Pandemic. Viruses 2023, 15, 1843, doi:10.3390/v15091843.

